In the last trading session, 70400.0 shares of the Foghorn Therapeutics Inc (NASDAQ:FHTX) were traded, and its beta was 3.08. Most recently the company’s share price was $4.14, and it changed around $0.0 or 0.00% from the last close, which brings the market valuation of the company to $230.77M. FHTX currently trades at a discount to its 52-week high of $10.25, offering almost -147.58% off that amount. The share price’s 52-week low was $2.94, which indicates that the current value has risen by an impressive 28.99% since then.
Foghorn Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 8 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 1 recommended FHTX as a Hold, whereas 5 deemed it a Buy, and 0 rated it as Underweight. Foghorn Therapeutics Inc is expected to report earnings per share of -0.32 for the current quarter.
Foghorn Therapeutics Inc (NASDAQ:FHTX) trade information
The performance over the last five days has remained in the red territory. The rise to weekly highs of 4.42 on recent trading dayincreased the stock’s daily price by 6.33%. The company’s shares are currently down -12.29% year-to-date, but still down -6.55% over the last five days. On the other hand, Foghorn Therapeutics Inc (NASDAQ:FHTX) is -7.38% down in the 30-day period.
The consensus price target as assigned by Wall Street analysts is $13, which translates to bulls needing to increase their stock price by 68.15% from its current value. Analyst projections state that FHTX is forecast to be at a low of $13 and a high of $13.
Foghorn Therapeutics Inc (FHTX) estimates and forecasts
The year-over-year growth rate is expected to be 30.98%, up from the previous year.
Consensus estimates provided by 5 financial analysts predict the company will bring in an average of 7.1M in revenue for the current quarter. 5 analysts expect Foghorn Therapeutics Inc to make 7.34M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 6.89M and 7.81M respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 3.03%. Forecasts for the next quarter put sales growth at -5.95%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -2.59%. Foghorn Therapeutics Inc earnings are expected to increase by 16.64% in 2025, but the outlook is positive 6.50% per year for the next five years.
FHTX Dividends
Foghorn Therapeutics Inc’s next quarterly earnings report is expected to be released in June.
FMR LLC, with 12.3754% or 6.38 million shares worth $36.7 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund were the top two Mutual Funds as of Mar 31, 2025 . The former held 1.86 shares worth $7.68 million, making up 3.33% of all outstanding shares. On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund held roughly 962.18 shares worth around $3.98 million, which represents about 1.73% of the total shares outstanding.
